A Phase III Trial Comparing Whole Brain Radiation And Stereotactic Radiosurgery Alone Versus With Temozolomide Or Erlotinib In Patients With Non-Small Cell Lung Cancer And 1-3 Brain Metastases.

Trial Profile

A Phase III Trial Comparing Whole Brain Radiation And Stereotactic Radiosurgery Alone Versus With Temozolomide Or Erlotinib In Patients With Non-Small Cell Lung Cancer And 1-3 Brain Metastases.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2013

At a glance

  • Drugs Erlotinib (Primary) ; Temozolomide (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov. (NCT00096265)
    • 19 Apr 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov. (NCT00096265)
    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00096265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top